ArticlePloS one2012
Staphylococcus aureus protein A plays a critical role in mediating bone destruction and bone loss in osteomyelitis.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 155 citations in OpenAlex.
- Osteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- Immune-activating PTL/nanowire composite coating on Ti surface enables macrophage-driven bacterial clearance and osseointegration.Bioactive materials · 2026Article
- ISO-1 sustained-release hydrogel repairs infected bone defects by suppressing osteoblast pyroptosis and enhancing osteogenic differentiation via the MIF-CD74/PI3K/AKT signaling pathway.Materials today. Bio · 2026Article
- Managing Bone Infections Beyond Systemic Antibiotics: A Scoping Review.Pathogens (Basel, Switzerland) · 2026Review
- Role of Cytokines in Bone Diseases and Their Therapeutic Application.ImmunoTargets and therapy · 2026Review
- Synergistic integration of biomaterials in orthopedic implantation for infection preventing and tissue engineering.Regenerative biomaterials · 2026Review
- The toxic effects of α-hemolysin and β-hemolysin produced byFrontiers in immunology · 2026Review
- Immunomodulatory Biomaterials for Bone and Soft Tissue Chronic Inflammation Diseases.Small science · 2025Review
- Virulence-Selective Trap-Capture-Kill Antibacterial Nanostructures With Immune-Metabolic Regulation for Treating Implant-Associated Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Programmed Transformation of Osteogenesis Microenvironment by a Multifunctional Hydrogel to Enhance Repair of Infectious Bone Defects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Biodegradable Janus sonozyme with continuous reactive oxygen species regulation for treating infected critical-sized bone defects.Nature communications · 2024Article
- Targeting Bacteria-Induced Ferroptosis of Bone Marrow Mesenchymal Stem Cells to Promote the Repair of Infected Bone Defects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The ever-changing microenvironment of Staphylococcus aureus in cutaneous infections.Animal models and experimental medicine · 2024Article
- Article
- Investigation on the molecular mechanism of SPA interference with osteogenic differentiation of bone marrow mesenchymal stem cells.Scientific reports · 2024Article
- Integrative gene expression analysis and animal model reveal immune- and autophagy-related biomarkers in osteomyelitis.Immunity, inflammation and disease · 2024Article
- Cannabidiol-loaded microparticles embedded in a porous hydrogel matrix for biomedical applications.Journal of materials science. Materials in medicine · 2024Article
- Non-biofilm-forming Staphylococcus epidermidis planktonic cell supernatant induces alterations in osteoblast biological function.Scientific reports · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is the most frequent causative organism of osteomyelitis. It is characterised by widespread bone loss and bone destruction. Previously we demonstrated that S. aureus protein A (SpA) is capable of binding to tumour necrosis factor receptor-1 expressed on pre-osteoblastic cells, which results in signal generation that leads to cell apoptosis resulting in bone loss. In the current report we demonstrate that upon S. aureus binding to osteoblasts it also inhibits de novo bone formation by preventing expression of key markers of osteoblast growth and division such as alkaline phosphatase, collagen type I, osteocalcin, osteopontin and osteocalcin. In addition, S. aureus induces secretion of soluble RANKL from osteoblasts which in turn recruits and activates the bone resorbing cells, osteoclasts. A strain of S. aureus defective in SpA failed to affect osteoblast growth or proliferation and most importantly failed to recruit or activate osteoclasts. These results suggest that S. aureus SpA binding to osteoblasts provides multiple coordinated signals that accounts for bone loss and bone destruction seen in osteomyelitis cases. A better understanding of the mechanisms through which S. aureus leads to bone infection may improve treatment or lead to the development of better therapeutic agents to treat this notoriously difficult disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.